Characteristics (n, %) or median (IQR) | hMPV infections Total (n=26) | hMPV infections Unmatched (n=10) | hMPV infections Matched (n=16) | Influenza infections (n=16) | P* |
---|---|---|---|---|---|
Age | 66 (56–74) | 62 (42–66) | 70 (58–76) | 69 (54–75) | 0.66 |
Gender (male) | 15 (57.6) | 6 (60.0) | 9 (56.3) | 11 (68.8) | 0.46 |
Hematological malignancy | |||||
Multiple myeloma | 8 (30.8) | 4 (40.0) | 4 (25) | 4 (25) | |
Lymphoma | 7 (26.9) | 3 (30.0) | 4 (25) | 5 (31.3) | |
Myeloproliferative disorder | 3 (11.5) | 2 (20.0) | 1 (6.3) | 1 (6.3) | 0.84 |
Acute leukemia | 2 (7.7) | 1 (10.0) | 1 (6.3) | 1 (6.3) | |
Myelodysplastic syndrome | 1 (3.8) | 0 (0) | 1 (6.3) | 0 (0) | |
Other comorbidities | |||||
Diabetes mellitus | 7 (26.9) | 0 (0) | 7 (43.8) | 7 (43.8) | 1 |
HIV infection | 3 (11.5) | 2 (20.0) | 1 (6.3) | 1 (6.3) | 1 |
Chronic respiratory failure | 6 (23.1) | 1 (10.0) | 5 (31.3) | 6 (37.5) | 0.70 |
Solid Cancer | 3 (11.5) | 1 (10.0) | 2 (12.5) | 0 (0) | 0.14 |
Steroids within the last 3 months | 11 (42.3) | 5 (50) | 6 (37.5) | 4 (25) | 0.70 |
Symptoms | |||||
SAPS 2 score | 41 (37–58) | 46 (40–58) | 40 (36–60) | 37 (30–47) | 0.44 |
Fever (>38°C) | 23 (88.5) | 8 (80.0) | 15 (93.8) | 14 (87.5) | 0.50 |
Shivers | 9 (34.6) | 3 (30.0) | 6 (37.5) | 4 (25) | 0.40 |
Flu-like syndrome | 5 (19.2) | 1 (10.0) | 4 (25) | 5 (31.3) | 0.70 |
ENT syndrome | 8 (30.8) | 2 (20.0) | 6 (37.5) | 3 (18.8) | 0.20 |
Cough | 19 (73.1) | 6 (60.0) | 13 (81.3) | 15 (93.8) | 0.30 |
Sputum | 9 (34.6) | 2 (20.0) | 7 (43.8) | 6 (37.5) | 0.70 |
Dyspnea | 24 (92.3) | 8 (80.0) | 16 (100) | 15 (93.8) | 0.30 |
Wheezing | 4 (15.4) | 2 (20.0) | 2 (12.5) | 5 (31.3) | 0.20 |
Thoracic pain | 1 (3.8) | 0 (0.0) | 1 (6.3) | 2 (12.5) | 0.50 |
Digestive symptoms | 7 (26.9) | 3 (30.0) | 4 (25) | 2 (12.5) | 0.40 |
Biology characteristics | |||||
Neutropenia | 7 (26.9) | 4 (40.0) | 3 (18.8) | 0 (0) | 0.07 |
Lymphopenia | 19 (73.1) | 9 (90.0) | 10 (62.5) | 10 (62.5) | 1 |
Chest X ray performed | 25 (96.2) | 10 (100) | 15 (93.8) | 16 (100) | |
Normal | 4 (16.0) ** | 2 (20) | 2 (13.3)** | 2 (12.5) | 1 |
Alveolar syndrome Interstitial syndrome | 6 (24.0) ** 20 (80.0) ** | 2 (20) 6 (60) | 4 (26.7)** 14 (93.3)** | 4 (25) 8 (50) | 1 0.25 |
Four quadrants involved | 12 (48.0) ** | 2 (20) | 10 (66.7)** | 3.(18.8) | 0.04 |
Pleural effusion | 5 (20.0) ** | 3 (30) | 2 (13.3)** | 0 (0) | 0.59 |
Ct scan performed | 14 (53.8) | 6 (60) | 8 (50) | 5 (31.3) | |
Ground glass opacities | 10 (66.8) ** | 4 (66.7)** | 6 (75)** | 3 (60)** | 0.04 |
Alveolar consolidation | 9 (60.0) ** | 4 (66.7)** | 5 (62.5)** | 3 (60)** | 0.72 |
Septal thickening | 3 (20.0) ** | 2 (33.3)** | 1 (12.5)** | 2 (40)** | 0.76 |
Nodular lesions | 9 (60.0) ** | 2 (33.3)** | 7 (87.5)** | 5 (100)** | 0.91 |
Crazy paving | 3 (20.0) ** | 2 (33.3)** | 1 (12.5)** | 2 (40)** | 0.76 |
Bronchial lesions | 2 (13.3) ** | 0 (0)** | 2 (25)** | 4 (80)** | 0.04 |
Coinfections | |||||
Viral | 8 (30.8) | 8 (80) | 0 (0) | 3 (18.8) | – |
Bacterial | 14 (53.8) | 5 (50) | 9 (56.3) | 3 (18.8) | 0.07 |
ICU management and outcomes | |||||
Symptoms duration before ICU admission | 7 (2–11) | 2 (1–7) | 9 (6–15) | 3 (2–5) | < 0.001 |
Mechanical ventilation | 10 (38.5) | 4 (40) | 6 (37.5) | 7 (43.8) | 0.72 |
ARDS | 5 (19.2) | 2 (20) | 3 (18.8) | 5 (31.2) | 0.68 |
Vasopressor support | 11 (42.3) | 7 (70) | 4 (25) | 9 (56.3) | 0.07 |
Renal replacement therapy | 4 (15.4) | 2 (20) | 2 (12.5) | 4 (25) | 0.36 |
Antibiotic duration | 11 (8–15) | 11 (8–13) | 8 (2–18) | 8 (7–14) | 0.85 |
Hospital length of stay (days) | 17 (9–27) | 18 (11–33) | 17 (8–25) | 10 (7–21) | 0.16 |
ICU length of stay (days) | 5 (3–8) | 6 (3–8) | 7 (5–11) | 5 (3–12) | 0.95 |
Hospital mortality | 8 (30.8) | 5 (50) | 3 (18.6) | 9 (56) | 0.03 |